The Joint National Committee 8 (JNC8) and the European Society of Hypertension (ESH) recommend that MR antagonists may be considered as the ‘fourth-line’ drug in the treatment of the resistant hypertension (Glicklich & Frishman 2015). This evidence concerns the gene NR3C2 and Hypertension.